TG Therapeutics, Inc.
TGTX
$48.74
$0.801.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 799.54M | 700.35M | 616.29M | 531.90M | 454.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 799.54M | 700.35M | 616.29M | 531.90M | 454.07M |
| Cost of Revenue | 140.94M | 118.68M | 100.71M | 77.97M | 59.22M |
| Gross Profit | 658.60M | 581.67M | 515.57M | 453.93M | 394.85M |
| SG&A Expenses | 296.47M | 269.92M | 232.03M | 208.25M | 186.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 663.21M | 550.85M | 492.96M | 429.12M | 368.22M |
| Operating Income | 136.33M | 149.50M | 123.32M | 102.78M | 85.85M |
| Income Before Tax | 101.60M | 122.29M | 107.39M | 87.75M | 66.11M |
| Income Tax Expenses | -339.89M | -339.61M | -339.79M | -359.72M | 5.65M |
| Earnings from Continuing Operations | 441.49 | 461.90 | 447.18 | 447.47 | 60.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 441.49M | 461.90M | 447.18M | 447.47M | 60.46M |
| EBIT | 136.33M | 149.50M | 123.32M | 102.78M | 85.85M |
| EBITDA | 136.45M | 149.58M | 123.38M | 102.83M | 85.89M |
| EPS Basic | 3.04 | 3.18 | 3.08 | 3.08 | 0.41 |
| Normalized Basic EPS | 0.48 | 0.57 | 0.46 | 0.38 | 0.28 |
| EPS Diluted | 2.74 | 2.86 | 2.77 | 2.78 | 0.37 |
| Normalized Diluted EPS | 0.43 | 0.51 | 0.42 | 0.34 | 0.26 |
| Average Basic Shares Outstanding | 574.59M | 579.56M | 581.80M | 584.08M | 583.76M |
| Average Diluted Shares Outstanding | 637.71M | 642.99M | 645.69M | 646.57M | 646.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |